New Enterprise Associates related stories
All articles and analysis
VC-backed Complexa recruits Salva as CEO and presidentBerwyn, Pennsylvania-based Complexa Inc, a biopharmaceutical company, has named Francisco D. Salva as CEO and president. His appointment is effective immediately. Previously, Salva was founder and vice president of operations for Acerta Pharma B.V. Complexa's backers include Andera Partners, HBM Healthcare Investments, JAFCO, New Enterprise Associates and Pfizer Venture Investments.
- Salesforce leads $24 mln funding of IFTTT
San Francisco-based IFTTT, which provides a utility for users to connect their apps, services and smart devices, announced it has raised $24 million in new funding led by Salesforce Ventures. IBM, Chamberlain Group and Fenox Venture Capital also participated in the round. IFTTT, which stand for "If This, Then That," was founded in 2010 and has now raised $63 million in total funding. Other investors include Andreessen Horowitz, Lerer Hippeau Ventures, New Enterprise Associates, Norwest Venture Partners and SV Angel.
- Aetion pockets $36.4 mln Series B
New York City-based Aetion, a provider of real-world analytics and evidence for biopharma customers and payers, has raised $36.4 million in Series B funding. New Enterprise Associates led the round with participation from Amgen Ventures, Flare Capital Partners, Lakestar and Oxeon Ventures. In addition to the funding, Mohamad Makhzoumi of NEA will join Aetion's board of directors.
- Expel attracts $20 mln Series B
Expel, a transparent managed security provider, has raised $20 million in Series B funding. Scale Venture Partners led the round. In conjunction with the funding, Ariel Tseitlin, a partner at Scale Venture Partners, will join Expel’s board of directors.
- VC-backed Cydan taps Babar as chief business officer
Cambridge, Massachusetts-based Cydan, an orphan drug accelerator, has named Dr. Imran A. Babar as chief business officer. Previously, Babar worked at OrbiMed Advisors. Cydan's backers include New Enterprise Associates, Pfizer Venture Investments, Lundbeckfonden Ventures, Longitude Capital and Alexandria Venture Investments.
Georgian invests in Welltok's $75 mln Series E2 roundU.S. consumer health enterprise software company Welltok Inc has secured US$75 million in a Series E2 financing. The round saw participation from both new and existing investors, including Canadian growth equity firm Georgian Partners. Denver, Colorado-based Welltok, founded in 2009, said the funds raised will be used for product development, expansion in new market segments, and integration of acquired assets and capabilities. Last October, the company bought Tea Leaves Health, an analytics and marketing platform used by hospital systems.
- Welltok racks up $75 mln
Welltok, a consumer health enterprise software-as-a-service company, has secured $75 million in Series E2 funding. The investors included Future Fund Management Agency, Ziff Davis, NF Trinity Capital (Hong Kong) Limited, ITOCHU Corporation, New Enterprise Associates, Bessemer Venture Partners and Georgian Partners.